ACM
SPRO icon

Aquilo Capital Management’s Spero Therapeutics SPRO Stock Holding History

Aquilo Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,403,210
Closed -$6.81M – 15
2022
Q3 		$6.81M Sell
3,403,210
-1,918,021
-36% -$1.91M 2.45% 13
2022
Q2 		$3.94M Buy
5,321,231
+39,727
+0.8% +$116K 1.35% 13
2022
Q1 		$45.9M Buy
5,281,504
+317,323
+6% +$3.25M 6.75% 6
2021
Q4 		$79.5M Buy
4,964,181
+400,493
+9% +$6.36M 9.01% 2
2021
Q3 		$84M Buy
4,563,688
+734,479
+19% +$11.8M 15.26% 2
2021
Q2 		$53.5M Hold
3,829,209
– – 13.89% 2
2021
Q1 		$56.4M Sell
3,829,209
-103,000
-3% -$1.81M 10.19% 3
2020
Q4 		$76.2M Sell
3,932,209
-564,933
-13% -$8.81M 15.85% 1
2020
Q3 		$50.2M Buy
4,497,142
+2,554,061
+131% +$30.2M 5.31% 3
2020
Q2 		$26.3M Buy
1,943,081
+124,941
+7% +$1.4M 5.3% 5
2020
Q1 		$14.7M Buy
1,818,140
+663,784
+58% +$5.85M 5.73% 6
2019
Q4 		$11.1M Hold
1,154,356
– – 4.17% 9
2019
Q3 		$12.2M Hold
1,154,356
– – 8.62% 5
2019
Q2 		$13.3M Buy
1,154,356
+100,000
+9% +$1.2M 4.61% 6
2019
Q1 		$13.5M Buy
1,054,356
+22,409
+2% +$238K 5.98% 6
2018
Q4 		$6.35M Buy
1,031,947
+232,256
+29% +$1.88M 3.07% 8
2018
Q3 		$8.4M Buy
799,691
+383,000
+92% +$4.44M 3.52% 9
2018
Q2 		$6.11M Buy
+416,691
New +$5.33M 5.04% 7

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aquilo Capital Management's SPRO Position: Q4 2022 in Review

Aquilo Capital Management sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 3,403,210 shares — an estimated $6.81M sold.

Aquilo Capital Management first reported a position in SPRO in Q2 2018 and held it in 18 quarters. The position peaked at $84M in Q3 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • Aquilo Capital Management reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Aquilo Capital Management sold 3,403,210 Spero Therapeutics shares in Q4 2022, an estimated $6.81M.
  • Aquilo Capital Management first reported a position in Spero Therapeutics in Q2 2018 and held it in 18 quarters.
  • Aquilo Capital Management's Spero Therapeutics position peaked at $84M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Aquilo Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.